Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

468.05 -4.68

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

459

Max

494.4

Belangrijke statistieken
By Trading Economics
Inkomsten	-36M -94M
Verkoop	-9.7M 311M
EPS	-1.38
Winstmarge	-30.318
Werknemers	915
EBITDA	-36M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+39.91% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	751M 13B
Vorige openingsprijs	472.73
Vorige sluitingsprijs	468.05

Nieuwssentiment

By Acuity

64%

36%

292 / 340 Rangschikking in Healthcare

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 jul 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29 jul 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28 jul 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27 jul 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 jul 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

39.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 689.93 USD 39.91%

Hoogste 964 USD

Laagste 543 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

292 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.